TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7307591
Drug: Indomethacin therapy
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin therapy
Study: 27744141
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg every 4 weeks plus DMARDs)
Study: 25623430
Drug: Antigen carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen carbohydrate 125-guided therapy
Study: 16037107
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol moistened with 3 ml of 5% acetic acid (group A, n = 33)
Study: 16037107
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol moistened with 3 ml of saline (group B, n = 33)
Study: 12074357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Candesartan 16 mg and Felodipine 5 mg
Study: 10583039
Drug: Grape juice
Normalized name: grape juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape juice (200 ml)
Study: 30666826
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg or 10 mg twice daily plus MTX
Study: 19057387
Drug: Cream intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream intake (highest quintile)
Study: 19057387
Drug: Total dairy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dairy, low-fat milk, sour milk, cheese, ice cream, butter intake
Study: 9610927
Drug: 4% BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% BCAA solution
Study: 9610927
Drug: 4% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amino acid solution
Study: 7821128
Drug: Sulfonylurea (glyburide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea (glyburide, G)
Study: 7821128
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (M/G, G/M, MGH)
Study: 7821128
Drug: Single-drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug therapy (M or G)
Study: 7821128
Drug: Low-dose primary
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose primary combination (MGL)
Study: 7821128
Drug: Glyburide alone
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide alone (G)
Study: 7821128
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (M and G)
Study: 7821128
Drug: Overall drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall drug safety
Study: 3270508
Drug: Hydroxyurea (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (500 mg orally every 4 hours for 3 days)
Study: 3270508
Drug: Etoposide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (100 mg/m2 per day by continuous infusion for 3 days)
Study: 3270508
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyurea and etoposide (fixed molar ratio of 58.9:1)
Study: 24534036
Drug: N alpha
Normalized name: Lutropin alpha
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N alpha methyl histamine (1 to 3 ug twice a week)
Study: 23437548
Drug: Vaccine candidate
Normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine candidate (live attenuated oral Vibrio cholerae Ol El Tor, Ogawa strain 638)
Study: 23437548
Drug: Vaccine candidate
Normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine candidate
Study: 15681602
Drug: Radiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy + Endocrine Therapy
Study: 15681602
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy Alone
Study: 21149918
Drug: Once-daily lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lamivudine
Study: 21149918
Drug: Once-daily abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily abacavir
Study: 21149918
Drug: Twice-daily lamivudine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily lamivudine
Study: 21149918
Drug: Twice-daily abacavir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily abacavir
Study: 21149918
Drug: Once-daily lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lamivudine and abacavir
Study: 11254911
Drug: No lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid lowering therapy
Study: 9647153
Drug: Diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (100 mg suppositories)
Study: 8090921
Drug: Gadoteridol at
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadoteridol at standard dose (0.1 mmol/kg)
Study: 8090921
Drug: Gadoteridol at
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadoteridol at triple dose (0.3 mmol/kg)
Study: 8090921
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of gadoteridol
Study: 2531389
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy (n = 26 after exclusions)
Study: 23723278
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (fixation of the clavicular fracture)
Study: 17943677
Drug: Remote administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote administration of the Functional Reach Test (FRT)
Study: 17943677
Drug: Remote administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remote administration of the European Stroke Scale (ESS)
Study: 17943677
Drug: Face-to-face administration
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administration of the Functional Reach Test (FRT)
Study: 17943677
Drug: Face-to-face administration
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administration of the European Stroke Scale (ESS)
Study: 11340701
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (BDP) 400 micrograms/day
Study: 9272245
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patch (Dermestril) with 25 micrograms/day
Study: 9272245
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patch (Dermestril) with 50 micrograms/day
Study: 9272245
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patch (Dermestril) with 100 micrograms/day
Study: 9272245
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal patch (Dermestril)
Study: 21920711
Drug: SSRI monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI monotherapy (escitalopram plus placebo)
Study: 21920711
Drug: Combination antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antidepressant medication (bupropion-sustained release plus escitalopram or venlafaxine-extended release plus mirtazapine)
Study: 15309376
Drug: LY354740 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY354740 (100 mg)
Study: 15309376
Drug: LY354740 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY354740 (400 mg)
Study: 10389719
Drug: 10-cm2 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-cm2 patch of 0.025 mg estradiol and 0.125 mg norethisterone acetate
Study: 10389719
Drug: 20-cm2 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-cm2 patch of 0.05 mg estradiol and 0.25 mg norethisterone acetate
Study: 10389719
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (2 mg estradiol and 1 mg norethisterone acetate)
Study: 31758571
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (10 days of rabeprazole, clarithromycin, amoxycillin, and tinidazole; 60 pills, cost US$10)
Study: 31758571
Drug: Concomitant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant therapy (14 days of rabeprazole, clarithromycin, amoxycillin, and tinidazole; 140 pills, cost US$23)
Study: 29665833
Drug: Bioactive vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive vitamin D (calcitriol) added to RAAS inhibition treatment using ACEI or ARB
Study: 28498184
Drug: ART failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART failure (HIVRNA ≥1000 copies/ml)
Study: 25748549
Drug: Exercise programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise programme (six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises)
Study: 18067975
Drug: Medication (tianeptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (tianeptine or fluoxetine) + Psychotherapy (supportive, cognitive-behavioral, or psychodynamic)
Study: 12676739
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg, orally) with placebo
Study: 12676739
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 mg, orally) with losartan (50 mg, orally)
Study: 1506604
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose ingestion in late pregnant women
Study: 1506604
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose ingestion in nonpregnant women
Study: 1506604
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g glucose ingestion in early pregnant women
Study: 30506745
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g micronized creatine monohydrate daily for three weeks; n=31)
Study: 26989892
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg arhalofenate
Study: 26989892
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg arhalofenate
Study: 18045815
Drug: L-carnitine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (20 mg x kg(‐1))
Study: 30681802
Drug: Ceramide containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramide containing cleanser and cream with salicylic acid, used twice daily for 28 days.
Study: 17632223
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 300 mg/d + high-dose dual nicotine replacement therapy (NRT) + weekly group cognitive behavioral therapy (CBT)
Study: 17632223
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + high-dose dual nicotine replacement therapy (NRT) + weekly group cognitive behavioral therapy (CBT)
Study: 15188360
Drug: Experimental intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental intervention (1-hour session with a nurse educator + monthly telephone counseling for 6 months)
Study: 15188360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (attention placebo: 45-minute video presentation about lupus + monthly telephone calls)
Study: 11457745
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (nifedipine or manidipine) (n=30)
Study: 3284316
Drug: Intravenous sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sotalol (1.5 mg/kg load followed by 0.008 mg/kg maintenance, mean dose 150 +/‐ 23 mg)
Study: 3284316
Drug: Oral sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sotalol (mean dose 583 +/‐ 204 mg daily)
Study: 27352488
Drug: Deep acupuncture
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep acupuncture at Lianquan (CV 23) and Yifeng (TE 17) combined with swallowing training (twice a day, 20 min per treatment)
Study: 25243955
Drug: Telbivudine (LdT)
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telbivudine (LdT) 600 mg once daily
Study: 25243955
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no LdT treatment)
Study: 22895585
Drug: HD-MTX-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-MTX-based chemotherapy
Study: 20388472
Drug: Qingshen Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingshen Granule (1 dosage each time, 3 times a day for one month)
Study: 11850136
Drug: Classroom‐centered (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom‐centered (CC) intervention
Study: 9012303
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no warming therapy)
Study: 386388
Drug: Racemic propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic propranolol (high doses)
Study: 31480866
Drug: Narratives reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narratives reporting Vaccine Adverse Events (VAE) at 35% frequency
Study: 31480866
Drug: Narratives reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narratives reporting Vaccine Adverse Events (VAE) at 5% frequency
Study: 26002878
Drug: IDAP Treatment
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDAP Treatment Program
Study: 23343704
Drug: palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: palmitoylethanolamide (PEA) 400 mg and transpolydatin 40 mg
Study: 17445927
Drug: Cisplatin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (6 mg/m2 i.v. x20, daily before RT) with RT (35 x 2 Gy)
Study: 17445927
Drug: Hydr‐Ac‐RT Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydr‐Ac‐RT Group (daily i.v. prehydration and accelerated RT)
Study: 2568792
Drug: Ionic monomeric
Normalized name: Monoferric
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ionic monomeric preparation
Study: 2568792
Drug: Nonionic monomeric
Normalized name: Monoferric
DrugBank: Ferric derisomaltose (DB15617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonionic monomeric preparation
Study: 1014119
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone
Study: 1014119
Drug: Alcohol infusion
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol infusion of the pituitary
Study: 23706959
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion policy (hemoglobin <8 g/dL)
Study: 23706959
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion policy (hemoglobin <10 g/dL)
Study: 15224295
Drug: Gamma-radiation therapy
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-radiation therapy (gamma-RT)
Study: 11282761
Drug: L-arginine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (0.5 g/10 kg body weight)
Study: 11282761
Drug: L-arginine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (1.5 g/10 kg body weight/d)
Study: 7815238
Drug: Lactose-free corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-free corn syrup-based milk formula
Study: 27773350
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation based on GEDI (goal-directed therapy until GEDI reached 800 mL/m2)
Study: 25256125
Drug: Topical hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hydrocortisone cream 1% (control group)
Study: 22948945
Drug: Chitin-glucan (CG)
Normalized name: Chitin
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitin-glucan (CG) 4.5 g/day
Study: 22948945
Drug: Chitin-glucan (CG)
Normalized name: Chitin
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitin-glucan (CG) 1.5 g/day
Study: 22948945
Drug: Chitin-glucan (CG)
Normalized name: Chitin
DrugBank: Chitin (DB15142)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitin-glucan (CG) 1.5 g/day plus olive oil (OO) extract 135 mg/day
Study: 16447104
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD) 7.5 mg/kg (group A)
Study: 16447104
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD) 10 mg/kg (group B)
Study: 16447104
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD) 15 mg/kg (group C)
Study: 12903909
Drug: 0.1 mol/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mol/l hydrochloric acid instillation
Study: 10769855
Drug: Midazolam, nalbuphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, nalbuphine, and droperidol administered intravenously, along with nitrous oxide and oxygen by nasal mask.
Study: 10769855
Drug: Midazolam, nalbuphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, nalbuphine, and droperidol administered intravenously.
Study: 9069567
Drug: Lower GIR
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower GIR group (insulin resistance)
Study: 9069567
Drug: Intermediate GIR
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate GIR group (insulin resistance)
Study: 9069567
Drug: Highest GIR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Highest GIR group (insulin resistance)
Study: 30600754
Drug: Intravenous 20
Normalized name: Dantrium Intravenous 20mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 20 mg nefopam in 100 mL normal saline before spinal anesthesia
Study: 30600754
Drug: Placebo: intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: intravenous normal saline 100 mL
Study: 22055594
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (20mg omeprazole bid, 1000mg amoxicillin bid, 500mg clarithromycin bid for 14 days)
Study: 22055594
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (20mg omeprazole bid and 1000mg amoxicillin bid for 14 days, 500mg ciprofloxacin bid for the first 7 days, 200mg furazolidone bid for the last 7 days)
Study: 22055594
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CrCl >90 mg/dl)
Study: 1329300
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg thrice daily for 1 week
Study: 22522357
Drug: Topical MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical MMR vaccine
Study: 20429049
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (GLU) 0.2 U/kg
Study: 20429049
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (ASP) 0.2 U/kg
Study: 12114885
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (n = 103)
Study: 7593777
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg daily for 12 weeks)
Study: 7580551
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg daily for 12 weeks)
Study: 2073105
Drug: Cefprozil 30
Normalized name: Cefprozil
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefprozil 30 mg/kg
Study: 2073105
Drug: Cis isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis isomer 15 mg/kg
Study: 2073105
Drug: Cis isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis isomer 30 mg/kg
Study: 2073105
Drug: Trans isomer
Normalized name: 3-butylidenephthalide, mixture of cis and trans isomers
DrugBank: Butylidenephthalide (DB17259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans isomer 15 mg/kg
Study: 2073105
Drug: Trans isomer
Normalized name: 3-butylidenephthalide, mixture of cis and trans isomers
DrugBank: Butylidenephthalide (DB17259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans isomer 30 mg/kg
Study: 17785486
Drug: In-treatment decrease
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment decrease of Cornell product (continuous variable)
Study: 17785486
Drug: In-treatment reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment reduction in Cornell product of 236 mm x msec or more
Study: 16135349
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV PCA) with morphine (1.5 mg; lockout interval, 8 min)